Professor Udai Banerji was awarded his PhD at The Institute of Cancer Research in 2005 and completed his medical oncology training at The Royal Marsden Hospital in 2007. He has been a honorary consultant at the Royal Marsden since 2007 and was appointed as NIHR Professor of Molecular Cancer Pharmacology in 2018.
He is the deputy head of the Drug Development Unit where he is involved in running the portfolio of more than 40 Phase I trials. He plays a key role bridging pre-clinical and clinical drug discovery designing and conducting phase I studies.
In addition to clinical trials Professor Banerji leads the Clinical Pharmacodynamics Biomarker Group and the Clinical Pharmacology – Adaptive Therapy groups at The Institute of Cancer Research. He laboratory interests include anticancer drug resistance and pharmacological aspects of cancer evolution.
Professor Banerji is part of the team that was awarded the prestigious American Association for Cancer Research (AACR) Team Science Award in 2012.